My watch list

Dexfenfluramine


Dexfenfluramine
Systematic (IUPAC) name
N-Ethyl-1-[3-(trifluoromethyl)phenyl]-propan-2-amine
Identifiers
CAS number	3239-44-9
ATC code	A08AA04
PubChem	3337
DrugBank	APRD00648
Chemical data
Formula	C₁₂H₁₆F₃N
Mol. mass	231.257 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	36%
Metabolism	?
Half life	17-20 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status	Schedule IV (US DEA)
Routes	?

Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by sibutramine, which is a safer alternative to both dexfenfluramine and fenfluramine.

Additional recommended knowledge

References

FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)

v • d • e Antiobesity preparations (A08)
Centrally acting	Phentermine - Fenfluramine - Amfepramone - Dexfenfluramine - Mazindol - Cathine - Clobenzorex - Sibutramine - Rimonabant
Peripherally acting	Orlistat